Definium Therapeutics (NASDAQ:DFTX) Downgraded to "Sell" Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Definium Therapeutics to “Sell” from “Hold,” contrasting with the broader analyst consensus of “Buy” and an average price target of $55.
• Shares opened at $46.14, near their 12-month high of $49.70, but the company reported a quarterly loss of $1.44 per share—well below the $0.55-per-share consensus estimate.
• Company insiders sold 48,096 shares worth approximately $2.17 million over the past three months, while institutional investors own 27.91% of the stock.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report released on Saturday.

Several other analysts also recently commented on the stock. Canaccord Genuity Group set a $58.00 price objective on shares of Definium Therapeutics and gave the company a "buy" rating in a research report on Tuesday, June 30th. Citigroup reaffirmed a "buy" rating on shares of Definium Therapeutics in a report on Monday, June 22nd. Robert W. Baird increased their price target on Definium Therapeutics from $37.00 to $57.00 and gave the stock an "outperform" rating in a research note on Tuesday, June 23rd. JonesTrading raised their price target on Definium Therapeutics from $61.00 to $74.00 and gave the company a "buy" rating in a report on Wednesday, June 24th. Finally, Piper Sandler reissued an "overweight" rating and set a $75.00 price target (up from $73.00) on shares of Definium Therapeutics in a report on Friday. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $55.00.

Definium Therapeutics Stock Performance

Definium Therapeutics stock opened at $46.14 on Friday. Definium Therapeutics has a 12-month low of $8.70 and a 12-month high of $49.70. The firm has a market capitalization of $4.60 billion, a price-to-earnings ratio of -13.45 and a beta of 2.23. The firm has a 50 day moving average of $37.89 and a 200 day moving average of $25.87. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.15.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.89). As a group, research analysts predict that Definium Therapeutics will post -2.27 earnings per share for the current year.

Insider Activity at Definium Therapeutics

In related news, CEO Robert Barrow sold 29,208 shares of the firm's stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $1,315,236.24. Following the completion of the transaction, the chief executive officer directly owned 1,098,246 shares of the company's stock, valued at approximately $49,454,017.38. This trade represents a 2.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Mark Sullivan sold 13,008 shares of the firm's stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $585,750.24. Following the transaction, the insider directly owned 320,571 shares of the company's stock, valued at $14,435,312.13. The trade was a 3.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 48,096 shares of company stock worth $2,165,763. 2.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Royal Bank of Canada increased its holdings in shares of Definium Therapeutics by 10.4% in the first quarter. Royal Bank of Canada now owns 65,237 shares of the company's stock worth $382,000 after purchasing an additional 6,148 shares during the last quarter. Creative Planning lifted its position in shares of Definium Therapeutics by 2.6% in the second quarter. Creative Planning now owns 66,097 shares of the company's stock worth $429,000 after buying an additional 1,655 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Definium Therapeutics by 5.1% during the second quarter. JPMorgan Chase & Co. now owns 48,487 shares of the company's stock valued at $315,000 after buying an additional 2,342 shares during the last quarter. Rhumbline Advisers boosted its stake in Definium Therapeutics by 6.3% during the second quarter. Rhumbline Advisers now owns 115,296 shares of the company's stock valued at $748,000 after buying an additional 6,839 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in Definium Therapeutics by 110.4% during the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company's stock valued at $25,000 after buying an additional 2,003 shares during the last quarter. Institutional investors own 27.91% of the company's stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source